U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
108721108721Phosphorylation of ERK1/2 in Patients With Parkinson's DiseaseCompletedNo Results AvailableParkinson DiseaseOther: Clinical variables|Other: Clinical variables|Other: Clinical variableshttps://ClinicalTrials.gov/show/NCT01142739
108722108722Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid ArthritisCompletedHas ResultsRheumatoid ArthritisDrug: Abatacept|Drug: Methotrexate|Drug: Abatacept placebo|Drug: Methotrexate placebohttps://ClinicalTrials.gov/show/NCT01142726
108723108723The Impact of Patient Positioning and Use of Belly Board on Small Bowel and Urinary Bladder Volume Irradiated in Patients Receiving Radiotherapy for Rectal Cancer: A Prospective Phase II StudyNot yet recruitingNo Results AvailableRectal CancerRadiation: Patient Position During Radiotherapyhttps://ClinicalTrials.gov/show/NCT01142713
108724108724A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype IWithdrawnNo Results AvailableChronic Hepatitis C Virus Genotype 1Drug: BMS-824393|Drug: BMS-824393|Drug: BMS-824393|Drug: Placebo|Drug: Peginterferon Alpha-2a|Drug: Ribavirinhttps://ClinicalTrials.gov/show/NCT01142700
108725108725Effects of Dihydrocapsiate on Adaptive and Diet-Induced Thermogenesis With a High Protein Very Low Calorie DietCompletedNo Results AvailableHealthyDietary Supplement: dihydrocapsiate capsulehttps://ClinicalTrials.gov/show/NCT01142687
108726108726T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell LymphomaRecruitingNo Results AvailableLymphoma, T-Cell, Peripheralhttps://ClinicalTrials.gov/show/NCT01142674
108727108727Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed TherapiesCompletedHas ResultsBreast CancerDrug: Eribulin Mesylatehttps://ClinicalTrials.gov/show/NCT01142661
108728108728Sugammadex and Brain WavesCompletedNo Results AvailableAnaesthesiaDrug: Sugammadex|Drug: Neostigmine and glycopyrrolatehttps://ClinicalTrials.gov/show/NCT01142648
108729108729Electromyographic (EMG) on the Anaesthesia MonitorCompletedNo Results AvailableAnaesthesiaDrug: Rocuronium bromide|Drug: Rocuronium bromidehttps://ClinicalTrials.gov/show/NCT01142635
108730108730Intraperitoneal Ropivacaine Nebulization for Pain Control After Gynecologic Laparoscopic SurgeryCompletedNo Results AvailableOvarian CystsDrug: Ropivacaine nebulization|Drug: Ropivacaine instillationhttps://ClinicalTrials.gov/show/NCT01142622
108731108731Improving Substance Abuse Counseling Adherence Using Web-based VideoconferencingCompletedNo Results AvailableSubstance Abuse DisorderBehavioral: eGethttps://ClinicalTrials.gov/show/NCT01142609
108732108732Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)CompletedNo Results AvailableSchizophreniaDrug: Asenapine|Drug: Asenapinehttps://ClinicalTrials.gov/show/NCT01142596
108733108733A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple SclerosisCompletedNo Results AvailableMultiple Sclerosis, Relapsing-Remittinghttps://ClinicalTrials.gov/show/NCT01142583
108734108734Effect of Enteral Nutrition Enriched in Protein and Based on Indirect Calorimetry Measurement in Chronically Critically Ill PatientsActive, not recruitingNo Results AvailableCritically IllOther: Caloric Support (Group 1)|Other: Caloric Support (Group 2)|Dietary Supplement: Protein dose of 1.1 to 1.5 grams per kilogram weight.|Dietary Supplement: Protein at 1.1 grams per kilogram weight.|Dietary Supplement: protein at a dose of 1.5 grams per kilogram weight.https://ClinicalTrials.gov/show/NCT01142570
108735108735An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple SclerosisCompletedNo Results AvailableMultiple SclerosisDrug: Interferon beta-1a (Rebif)https://ClinicalTrials.gov/show/NCT01142557
108736108736Incidence of Acute Lung Injury in ChildrenCompletedNo Results AvailableAcute Lung Injury|ChildrenOther: Evaluation oxygenation under standard ventilator settingshttps://ClinicalTrials.gov/show/NCT01142544
108737108737Effects of Bronchodilation on Computed Tomography (CT) Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent.CompletedNo Results AvailableCOPD|CT|BronchodilationRadiation: Chest CT scanhttps://ClinicalTrials.gov/show/NCT01142531
108738108738An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With MitoxantroneCompletedNo Results AvailableRelapsing-Remitting Multiple SclerosisDrug: Interferon beta 1ahttps://ClinicalTrials.gov/show/NCT01142518
108739108739Wheeze and Intermittent TreatmentCompletedNo Results AvailableWheezingDrug: Mannitol|Drug: Montelukasthttps://ClinicalTrials.gov/show/NCT01142505
108740108740A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)CompletedNo Results AvailableRelapsing-Remitting Multiple SclerosisDrug: Interferon beta-1ahttps://ClinicalTrials.gov/show/NCT01142492
108741108741Compound Herbal Formula (TPE-1) for Leukopenia and Cancer-related Fatigue in Breast Cancer Patients With RadiotherapyCompletedNo Results AvailableBreast Cancer|Radiotherapy|Chinese Herbal MedicineDrug: Chinese herbal medicine decoctionhttps://ClinicalTrials.gov/show/NCT01142479
108742108742A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After MitoxantroneCompletedHas ResultsMultiple Sclerosis, Relapsing-RemittingDrug: Interferon beta-1a (Rebif)https://ClinicalTrials.gov/show/NCT01142466
108743108743An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) PatientsCompletedNo Results AvailableRelapsing-Remitting Multiple SclerosisDrug: Interferon beta 1ahttps://ClinicalTrials.gov/show/NCT01142453
108744108744Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among (IDF) PersonnelRecruitingNo Results AvailableDental CariesBehavioral: behavioral interventionhttps://ClinicalTrials.gov/show/NCT01142440
108745108745Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaRecruitingNo Results AvailableAdult B Acute Lymphoblastic Leukemia|Adult T Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia|Childhood T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic LeukemiaOther: Laboratory Biomarker Analysis|Other: Cytology Specimen Collection Procedurehttps://ClinicalTrials.gov/show/NCT01142427
108746108746Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of RecurrenceWithdrawnNo Results AvailableHead and Neck CancerBiological: panitumumab|Drug: cisplatin|Drug: fluorouracil|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: quality-of-life assessment|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapyhttps://ClinicalTrials.gov/show/NCT01142414
108747108747Fulvestrant With or Without Bortezomib in Postmenopausal Women With Locally Advanced or Metastatic Breast CancerActive, not recruitingNo Results AvailableEstrogen Receptor Positive|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast CancerDrug: Bortezomib|Drug: Fulvestrant|Other: Laboratory Biomarker Analysishttps://ClinicalTrials.gov/show/NCT01142401
108748108748Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction CancerActive, not recruitingHas ResultsAdenocarcinoma of the Gastroesophageal Junction|Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Recurrent Esophageal Carcinoma|Stage IV Esophageal CancerBiological: Cixutumumab|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Pharmacological Studyhttps://ClinicalTrials.gov/show/NCT01142388
108749108749Development and Exploration of the Feasibility of Using Locally Synthesized Small Molecule Inhibitors to Treat Human Acute Leukemia CellsActive, not recruitingNo Results AvailableAcute Myeloid Leukemiahttps://ClinicalTrials.gov/show/NCT01142375
108750108750Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy AdultsCompletedNo Results AvailableHealthyBiological: VGX-3400Xhttps://ClinicalTrials.gov/show/NCT01142362

* Görseller ve İçerik tekif hakkına sahip olabilir